Managing Director of the Belgian company "RovalPharma" Roland Schotts arrived at the Institute of Nuclear Physics. Roland Schotts is an international professional expert in the field of industrial pharmacology.
The purpose of the visit is an independent examination of the GMP (Good Manufacturing Practice) requirements of the site for the production of radiopharmaceuticals at the Scientific-Technical Center for Radiochemistry and Isotope Production of the Institute of Nuclear Physics. Despite the fact that the production of radiopharmaceuticals at the Institute is accredited under the GMP system, an independent assessment by an international expert will attract foreign investors for the development and implementation of the production of new radiopharmaceuticals at the Institute of Nuclear Physics.
It should be noted that in 2019, the Institute of Nuclear Physics was the first among manufacturers of radiopharmaceuticals who received a GMP certificate, confirming its readiness to guarantee high-quality products. This certificate confirms that the production process complies with international standards - drug consumers can rest assured about their health.
The laboratory was inspected in 2018. After receiving the certificate, the Institute launched the production of vital radioisotopes. Today, the Institute regularly produces (75% of total production of radiopharmaceuticals in the Republic of Kazakhstan) and supplies these radiopharmaceuticals to medical institutions of the Republic of Kazakhstan. At the end of 2022, the production of radioactive isotopes increased by 114% compared to 2021. In 2022, cobalt-57 was supplied to Germany for the first time.
